Safety of long-term monthly cycles of methylprednisolone in combination with interferon β-1a IM in treatment-naive early relapsing-remitting multiple sclerosis patients in the MECOMBIN trial

被引：0
|
作者：
Ravnborg, M.
Sorensen, P. S.
Andersson, M.
Celius, E. Gulowsen
Jongen, P.
Batholome, E.
Elovaara, I.
Beer, K.
Sperling, B.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [41] Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
    Planas, Raquel
    Martin, Roland
    Sospedra, Mireia
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 25 - 33
  • [42] Interferon beta 1a treatment induces the presence of autoreactive antibodies (ARAB) in patients with relapsing-remitting multiple sclerosis (RRMS)
    Papastergios, Chrysostomos
    Karamouzos, Emmanouil
    Markakis, Ioannis
    Kaliouli, Christiana
    Eleni, Pappa
    Gekas, Georgios
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 167 - 167
  • [43] Interferon β1a Treatment Modulates TH1 Expression in γδ + T Cells from Relapsing-Remitting Multiple Sclerosis Patients
    Cerise L. Elliott
    Samia Y. Ei-Touny
    Mary L. Filipi
    Kathleen M. Healey
    M. Patricia Leuschen
    Journal of Clinical Immunology, 2001, 21 : 200 - 209
  • [44] Long Term Effect of Interferon-Beta on Disease Severity in Relapsing-Remitting Multiple Sclerosis Patients
    Patrucco, Liliana B.
    Rojas, Juan I.
    Cristiano, Edgardo
    NEUROLOGY, 2009, 72 (11) : A235 - A235
  • [45] Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients
    Patrucco, Liliana
    Ignacio Rojas, Juan
    Cristiano, Edgardo
    REVISTA DE NEUROLOGIA, 2010, 50 (09) : 529 - 532
  • [46] Interferon β-1a and depression in relapsing-remitting multiple sclerosis:: an analysis of depression data from the PRISMS clinical trial
    Patten, SB
    Metz, LM
    MULTIPLE SCLEROSIS, 2001, 7 (04): : 243 - 248
  • [47] Long-term follow-up of immunomodulatory therapies in early relapsing-remitting multiple sclerosis
    Haas, Judith
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S45 - S46
  • [48] Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis
    Castillo-Trivino, Tamara
    Gomez-Ballesteros, Rocio
    Borges, Monica
    Martin-Martinez, Jesils
    Sotoca, Javier
    Alonso, Ana
    Caminero Rodriguez, Ana Belen
    Borrega, Laura
    Sanchez-Menoyo, Jose Luis
    Barrero-Hernandez, Francisco
    Calles, Carmen
    Ruiz, Luis Brieva
    Blasco, Maria R.
    Garcia-Soto, Julio Dotor
    Del Campo-Amigo, Maria
    Navarro-Canto, Laura
    Morales, Eduardo Aguera
    Garces, Moises
    Codina, Olga Carmona
    Gabaldon-Torres, Laura
    Forero, Lucia
    Hervas, Mariona
    Maurino, Jorge
    de la Maza, Susana Sainz
    NEUROLOGY, 2022, 98 (18)
  • [49] Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Wells, C.
    Leppert, D.
    Glanzman, R.
    Tinbergen, J.
    Hauser, S.
    JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S65
  • [50] Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the 'old' therapies?
    Heidenreich, F.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11): : 1171 - 1171
12345